Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 2 (2005), Issue 12 (December)

1. Ultrasound mapping of lymph node and subcutaneous metastases in patients with cutaneous melanoma: results of a prospective multicenter study.
   Dermatology, 212(1): 47-52. [Abstract] [Full-text]
2. Molecular targets in melanoma: strategies and challenges for diagnosis and therapy.
   Int J Cancer, 118(3): 523-6. [Abstract] [Full-text]
3. Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas.
   Int J Cancer, 118(3): 577-82. [Abstract] [Full-text]
4. Revealing the genomic heterogeneity of melanoma.
   Cancer Cell, 8(6): 439-41. [Abstract] [Full-text]
5. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
   J Clin Oncol, 23(35): 9001-7. [Abstract] [Full-text]
6. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
   J Clin Oncol, 23(35): 8978-91. [Abstract] [Full-text]
7. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
   J Clin Oncol, 23(35): 8992-9000. [Abstract] [Full-text]
8. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
   J Clin Oncol, 23(35): 8968-77. [Abstract] [Full-text]
9. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
   J Clin Oncol, 23(35): 9008-21. [Abstract] [Full-text]
10. Microsatellite instability and alterations of mismatch repair protein expression in choroidal melanomas.
    Arch Ophthalmol, 123(12): 1705-11. [Abstract] [Full-text]
11. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26.
    Arch Ophthalmol, 123(12): 1639-43. [Abstract] [Full-text]
12. Effects of pulsed magnetic stimulation on tumor development and immune functions in mice.
    Bioelectromagnetics, 27(1): 64-72. [Abstract] [Full-text]
13. Characterization of glycosylation and adherent properties of melanoma cell lines.
    Cancer Immunol Immunother, 55(1): 112-8. [Abstract] [Full-text]
14. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
    Clin Cancer Res, 11(24): 8606-14. [Abstract] [Full-text]
15. Lipocalin-type prostaglandin D synthase as a melanocyte marker regulated by MITF.
    Biochem Biophys Res Commun, 339(4): 1098-106. [Abstract] [Full-text]
16. Patterns of recurrence in patients with melanoma after radical lymph node dissection.
    Arch Surg, 140(12): 1172-7. [Abstract] [Full-text]
17. Choroidal biopsies for intraocular tumors of indeterminate origin.
    Am J Ophthalmol, 140(6): 1002-6. [Abstract] [Full-text]
18. Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status.
    Int J Cancer, 118(5): 1135-43. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.